When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
OBSV - ObsEva's linzagolix successful in late-stage uterine fibroid study
ObsEva SA
ObsEva SA (NASDAQ:OBSV) announces positive results from a Phase 3 clinical trial, PRIMROSE 1, evaluating Yselty (linzagolix) in women with heavy menstrual bleeding due to uterine fibroids.
More news on: ObsEva SA, Healthcare stocks news, Stocks on the move,